Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Cytoreduction for ET and PV: who, what, when, and how?
Douglas Tremblay
Icahn School of Medicine at Mount Sinai
Research output
:
Contribution to journal
›
Review article
›
peer-review
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cytoreduction for ET and PV: who, what, when, and how?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Essential Thrombocythemia
100%
Polycythemia Vera
100%
Cytoreduction
100%
Cytoreductive Surgery
60%
Interferon-α (IFN-α)
20%
Risk Stratification
20%
Clinical High Risk
20%
Treatment Goals
20%
Toxicity Profile
20%
Thrombotic Complications
20%
Hydroxyurea
20%
Personalized Care
20%
Individual Treatment
20%
Ruxolitinib
20%
Thromboembolism Prevention
20%
Anagrelide
20%
High Thrombotic Risk
20%
Medicine and Dentistry
Essential Thrombocythaemia
100%
Polycythemia vera
100%
Interferon
20%
Disease
20%
Risk Stratification
20%
Hydroxyurea
20%
Ruxolitinib
20%
Thrombosis Prevention
20%
Anagrelide
20%